Sansure Biotech Inc. (SHA:688289)

Market Cap	10.48B -25.3%
Revenue (ttm)	1.65B +13.0%
Net Income	198.15M -28.1%
EPS	0.34 -27.7%
Shares Out	574.18M
PE Ratio	53.71
Forward PE	28.53
Dividend	0.54 (2.94%)
Ex-Dividend Date	n/a

Volume	3,234,468
Average Volume	3,640,548
Open	18.25
Previous Close	18.26
Day's Range	18.15 - 18.33
52-Week Range	17.58 - 23.45
Beta	0.66
RSI	46.62
Earnings Date	Apr 30, 2026

About Sansure Biotech

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; an...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2008
• Employees: 2,409
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688289

Financial Performance

In 2025, Sansure Biotech's revenue was 1.65 billion, an increase of 13.04% compared to the previous year's 1.46 billion. Earnings were 198.15 million, a decrease of -28.10%.